Diverse ways of perturbing the human arachidonic acid metabolic network to control inflammation.
暂无分享,去创建一个
[1] Péter Csermely,et al. The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.
[2] Y. Liu,et al. Activation and inhibition of leukotriene A4 hydrolase aminopeptidase activity by diphenyl ether and derivatives. , 2008, Bioorganic & medicinal chemistry letters.
[3] M. Hamberg,et al. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[4] L. Lai,et al. Dynamic modeling of human 5-lipoxygenase-inhibitor interactions helps to discover novel inhibitors. , 2012, Journal of medicinal chemistry.
[5] S. Laufer,et al. (6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. , 1994, Journal of medicinal chemistry.
[6] Oliver Werz,et al. Multi-target approach for natural products in inflammation. , 2014, Drug discovery today.
[7] T. Willson,et al. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase , 1999, Nature.
[8] D. Garvey,et al. Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. , 2007, Current topics in medicinal chemistry.
[9] M. Paige,et al. Effect of the leukotriene A4 hydrolase aminopeptidase augmentor 4-methoxydiphenylmethane in a pre-clinical model of pulmonary emphysema. , 2011, Bioorganic & medicinal chemistry letters.
[10] L. Lai,et al. Identifying Allosteric Binding Sites in Proteins with a Two-State Go̅ Model for Novel Allosteric Effector Discovery. , 2012, Journal of chemical theory and computation.
[11] M. Doble,et al. Leukotriene c4 synthase: upcoming drug target for inflammation. , 2012, Current drug targets.
[12] G. Schneider,et al. Aminothiazole-featured pirinixic acid derivatives as dual 5-lipoxygenase and microsomal prostaglandin E2 synthase-1 inhibitors with improved potency and efficiency in vivo. , 2013, Journal of medicinal chemistry.
[13] O. Werz,et al. Discovery of Depsides and Depsidones from Lichen as Potent Inhibitors of Microsomal Prostaglandin E2 Synthase‐1 Using Pharmacophore Models , 2012, ChemMedChem.
[14] Jianfeng Pei,et al. Binding site detection and druggability prediction of protein targets for structure-based drug design. , 2013, Current pharmaceutical design.
[15] M. Percival,et al. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. , 1999, Bioorganic & medicinal chemistry letters.
[16] R. Copeland,et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[17] B D Hammock,et al. Rationally designed multitarget agents against inflammation and pain. , 2013, Current medicinal chemistry.
[18] A. M. Lefer,et al. Thromboxane A2, prostacyclin and aspirin: effects on vascular tone and platelet aggregation. , 1980, Circulation.
[19] A. Barabasi,et al. Network medicine : a network-based approach to human disease , 2010 .
[20] Kiyoko F. Aoki-Kinoshita,et al. From genomics to chemical genomics: new developments in KEGG , 2005, Nucleic Acids Res..
[21] S. Missailidis,et al. Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. , 2009, International immunopharmacology.
[22] Luhua Lai,et al. Differential simulated annealing: a robust and efficient global optimization algorithm for parameter estimation of biological networks. , 2014, Molecular bioSystems.
[23] Luhua Lai,et al. Discovery of dual target inhibitors against cyclooxygenases and leukotriene A4 hydrolyase. , 2011, Journal of medicinal chemistry.
[24] M. Leslie. Inflammation's stop signals. , 2015, Science.
[25] D. W. Anderson,et al. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. , 1994, The Journal of pharmacology and experimental therapeutics.
[26] Luhua Lai,et al. LigBuilder: A Multi-Purpose Program for Structure-Based Drug Design , 2000 .
[27] David L Mobley,et al. Quantifying Correlations Between Allosteric Sites in Thermodynamic Ensembles. , 2009, Journal of chemical theory and computation.
[28] Boon Chuan Low,et al. In-Silico Approaches to Multi-target Drug Discovery , 2010, Pharmaceutical Research.
[29] D. Steinhilber,et al. Inhibitors of the arachidonic acid cascade: interfering with multiple pathways. , 2014, Basic & clinical pharmacology & toxicology.
[30] T. Lu,et al. Discovery of potential anti-inflammatory drugs: diaryl-1,2,4-triazoles bearing N-hydroxyurea moiety as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase. , 2014, Organic & biomolecular chemistry.
[31] O. Werz,et al. Identification of 2-mercaptohexanoic acids as dual inhibitors of 5-lipoxygenase and microsomal prostaglandin E₂ synthase-1. , 2011, Bioorganic & medicinal chemistry.
[32] K. Honn,et al. Prostacyclin: a potent antimetastatic agent. , 1981, Science.
[33] R. S. Rogers,et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). , 1997, Journal of medicinal chemistry.
[34] Richard Morphy,et al. Designed Multiple Ligands. An Emerging Drug Discovery Paradigm , 2006 .
[35] Luhua Lai,et al. Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. , 2008, Journal of medicinal chemistry.
[36] A. Gaggar,et al. A Critical Role for LTA4H in Limiting Chronic Pulmonary Neutrophilic Inflammation , 2010, Science.
[37] Luhua Lai,et al. Dynamic Simulations on the Arachidonic Acid Metabolic Network , 2007, PLoS Comput. Biol..
[38] Charles N. Serhan,et al. Lipid mediator class switching during acute inflammation: signals in resolution , 2001, Nature Immunology.
[39] E. Craige,et al. Enhancement of Tactile Perception in Palpation , 1980, Circulation.
[40] Jianfeng Pei,et al. Systems biology brings new dimensions for structure-based drug design. , 2014, Journal of the American Chemical Society.
[41] O. Werz,et al. Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. , 2008, Journal of medicinal chemistry.
[42] B. Psaty,et al. COX-2 inhibitors--lessons in drug safety. , 2005, The New England journal of medicine.
[43] Jianfeng Pei,et al. Understanding molecular mechanisms of traditional Chinese medicine for the treatment of influenza viruses infection by computational approaches. , 2013, Molecular bioSystems.
[44] T. Penning. Inhibitors of leukotriene A4 (LTA4) hydrolase as potential anti-inflammatory agents. , 2001, Current pharmaceutical design.
[45] Jing Chen,et al. Pocket v.2: Further Developments on Receptor-Based Pharmacophore Modeling , 2006, J. Chem. Inf. Model..
[46] Debashis Singh,et al. FDA to review risks of antidepressants in adults , 2004, BMJ : British Medical Journal.
[47] Luhua Lai,et al. Dynamic eicosanoid responses upon different inhibitor and combination treatments on the arachidonic acid metabolic network. , 2012, Molecular bioSystems.
[48] S. Yamamoto,et al. Inhibition of leukotriene synthesis by azelastine. , 1996, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[49] O. Werz,et al. Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX). , 2009, Journal of medicinal chemistry.
[50] C. Serhan. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. , 2007, Annual review of immunology.
[51] W. Berger,et al. Zileuton: clinical implications of 5‐Lipoxygenase inhibition in severe airway disease , 2007, International journal of clinical practice.
[52] J. Gierse,et al. Structure−Activity Relationship Studies on 1-[2-(4-Phenylphenoxy)ethyl]pyrrolidine (SC-22716), a Potent Inhibitor of Leukotriene A4 (LTA4) Hydrolase , 2000 .
[53] Y. Liu,et al. Modulating the Substrate Specificity of LTA4H Aminopeptidase by Using Chemical Compounds and Small‐Molecule‐Guided Mutagenesis , 2010, Chembiochem : a European journal of chemical biology.
[54] Luhua Lai,et al. Optimization of 5-hydroxytryptamines as dual function inhibitors targeting phospholipase A2 and leukotriene A4 hydrolase. , 2013, European journal of medicinal chemistry.
[55] Ruth Nussinov,et al. Structure and dynamics of molecular networks: A novel paradigm of drug discovery. A comprehensive review , 2012, Pharmacology & therapeutics.
[56] Luhua Lai,et al. Benzo[d]isothiazole 1,1-dioxide derivatives as dual functional inhibitors of 5-lipoxygenase and microsomal prostaglandin E(2) synthase-1. , 2014, Bioorganic & medicinal chemistry letters.
[57] A. Togias,et al. Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis , 2006, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[58] L. Lai,et al. Finding multiple target optimal intervention in disease-related molecular network , 2008, Molecular systems biology.
[59] A. Lomas,et al. Acute and chronic effects of tepoxalin on kidney function in dogs with chronic kidney disease and osteoarthritis. , 2013, American journal of veterinary research.
[60] Min He,et al. Traditional Chinese Medicine Database and Application on the Web , 2001, J. Chem. Inf. Comput. Sci..
[61] Zhe Shi,et al. Computer Aided Multi-target Drug Design, Multi-target Virtual Screening , 2010 .
[62] Luhua Lai,et al. LigBuilder 2: A Practical de Novo Drug Design Approach , 2011, J. Chem. Inf. Model..
[63] Ying Liu,et al. De Novo Design of Multitarget Ligands with an Iterative Fragment-Growing Strategy , 2014, J. Chem. Inf. Model..
[64] L. Lai,et al. Discovery of highly potent microsomal prostaglandin e2 synthase 1 inhibitors using the active conformation structural model and virtual screen. , 2013, Journal of medicinal chemistry.
[65] A. Ford-hutchinson,et al. The role of arachidonic acid oxygenation products in pain and inflammation. , 1984, Annual review of immunology.
[66] K. Yasui,et al. Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase. , 2000, Journal of medicinal chemistry.
[67] Jianfeng Pei,et al. Understanding traditional Chinese medicine anti-inflammatory herbal formulae by simulating their regulatory functions in the human arachidonic acid metabolic network. , 2013, Molecular bioSystems.